81250-28-4

Usage

Type

Xanthine derivative

Function

Non-selective inhibitor of phosphodiesterases and adenosine receptors

Application

Scientific research tool for studying cAMP-dependent signaling pathways

Mechanism of Action

Increases intracellular cAMP levels by inhibiting its degradation

Effect on Signaling Pathways

Activation of protein kinase A and downstream signaling cascades

Therapeutic Potential

Being investigated for treating asthma, chronic obstructive pulmonary disease, and hypertension

Additional Use

Pharmacological tool to enhance the effects of other drugs and compounds

Importance

Valuable tool in biomedical and pharmaceutical research due to its wide range of biological activities

InChI:InChI=1/C14H22N4O2/c1-8(2)6-17-12-11(15-10(5)16-12)13(19)18(14(17)20)7-9(3)4/h8-9H,6-7H2,1-5H3,(H,15,16)

Upstream product

• 1189-23-7 N,N'-di-isobutylurea 
• 120562-81-4 1,3-diisobutyl-4-amino-5-nitrosouracil 
• 81250-36-4 1,3-diisobutyl-4-aminouracil 
• 120562-82-5 1,3-diisobutyl-4,5-diaminouracil 
• 64-19-7 acetic acid 

Relevant academic research and scientific papers

Use of 1,3-diisobutyl-8-methylxanthine as a bronchodilator and antiallergy agent

The invention relates to the use of 1,3-diisobutyl-8--methylxanthine, or its pharmaceutically acceptable salts, for the treatment or prophylaxis of acute or chronic obstructive airways disease and allergic asthma. The invention also relates to a pharmaceutical composition of an aerosol containing 1,3-diisobutyl-8-methylxanthine, ethanol, sorbitan oleate and one or more freons.

Structure-activity relationships in a series of xanthine derivatives with antibronchoconstrictory and bronchodilatory activities

Thirty-one 1,3,7,8-substituted xanthine derivatives have been synthesized and evaluated for bronchodilator and anti-bronchoconstrictory activities in in vitro tracheal relaxation and in vivo bronchospasm inhibition models. Activity tests have been complemented with phosphodiesterase inhibition and toxicological data. Structure-activity relationships are discussed. Compound 21 (1,3-diisobutyl-8-methylxanthine) has been selected for further pharmacological development because of its good activity profile and favourable therapeutic index, which is 14- and 38-fold greater than that of theophylline and IBMX, respectively.

Di- or trisubstituted xanthines with neuroleptic properties and composition

The invention relates to xanthines corresponding to the formula STR1 and physiologically acceptable salts thereof, in which R1 represents C2 -C4 -alkyl, C3 -C4 -isoalkyl, CH2 -(C2 -C3 -alkenyl) or CH2 -(C3 -isoalkenyl); R3 represents C3 -C5 -alkyl, C3 -C5 -isoalkyl, CH2 -(C2 -C4 -alkenyl) or CH2 -(C3 -C4 -isoalkenyl); R8 represents H, methyl or ethyl; with the proviso that (1) when R8 represents H, R1 is allyl and (2) R1 and R3 cannot both represent butyl or allyl at the same time. The compounds show non-specific or anxiolytic sedative activity.